{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T23:09:45Z","timestamp":1791328185715,"version":"4.3.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2016,2,15]],"date-time":"2016-02-15T00:00:00Z","timestamp":1455494400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Hematol Malig Rep"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1007\/s11899-016-0306-5","type":"journal-article","created":{"date-parts":[[2016,2,15]],"date-time":"2016-02-15T07:38:58Z","timestamp":1455521938000},"page":"80-85","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["Quality of Life and Long-Term Therapy in Patients with Chronic Myeloid Leukemia"],"prefix":"10.1007","volume":"11","author":[{"given":"Kathryn E.","family":"Flynn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ehab","family":"Atallah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,2,15]]},"reference":[{"key":"306_CR1","first-page":"2773","volume":"126","author":"S Saussele","year":"2015","unstructured":"Saussele S, Stein M, Gil A, Kossak-Roth U, Lauseker M, Proetel U, et al. Health-related quality of life impairment in patients with chronic myeloid leukemia: results of a German cross-sectional study of patients registered in prospective. Control Clin Trials Blood. 2015;126:2773.","journal-title":"Control Clin Trials Blood"},{"key":"306_CR2","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1038\/leu.2013.51","volume":"27","author":"F Efficace","year":"2013","unstructured":"Efficace F, Baccarani M, Breccia M, Cottone F, Alimena G, Deliliers GL, et al. Chronic fatigue is the most important factor limiting health-related quality of life of chronic myeloid leukemia patients treated with imatinib. Leukemia. 2013;27:1511\u20139.","journal-title":"Leukemia"},{"key":"306_CR3","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.leukres.2012.10.021","volume":"37","author":"F Efficace","year":"2013","unstructured":"Efficace F, Cardoni A, Cottone F, Vignetti M, Mandelli F. Tyrosine-kinase inhibitors and patient-reported outcomes in chronic myeloid leukemia: a systematic review. Leuk Res. 2013;37:206\u201313.","journal-title":"Leuk Res"},{"key":"306_CR4","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1185\/03007995.2014.944973","volume":"30","author":"A Guerin","year":"2014","unstructured":"Guerin A, Chen L, Ionescu-Ittu R, Marynchenko M, Nitulescu R, Hiscock R, et al. Impact of low-grade adverse events on health-related quality of life in adult patients receiving imatinib or nilotinib for newly diagnosed Philadelphia chromosome positive chronic myelogenous leukemia in chronic phase. Curr Med Res Opin. 2014;30:2317\u201328.","journal-title":"Curr Med Res Opin"},{"key":"306_CR5","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1038\/leu.2015.36","volume":"29","author":"L Kalmanti","year":"2015","unstructured":"Kalmanti L, Saussele S, Lauseker M, Muller MC, Dietz CT, Heinrich L, et al. Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV. Leukemia. 2015;29:1123\u201332. 10-year follow-up of imatinib therapy. A comprehensive analysis of imatinib therapy in CML.","journal-title":"Leukemia"},{"key":"306_CR6","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1182\/blood-2013-06-511592","volume":"123","author":"E Jabbour","year":"2014","unstructured":"Jabbour E, Kantarjian HM, Saglio G, Steegmann JL, Shah NP, Boqu\u00e9 C, et al. Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION). Blood. 2014;123:494\u2013500.","journal-title":"Blood"},{"key":"306_CR7","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1182\/blood.V124.21.152.152","volume":"124","author":"JE Cortes","year":"2014","unstructured":"Cortes JE, Saglio G, Baccarani M, Kantarjian HM, Mayer J, Boqu\u00e9 C, et al. Final study results of the phase 3 dasatinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) trial (DASISION, CA180-056). Blood. 2014;124:152.","journal-title":"Blood"},{"key":"306_CR8","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1182\/blood-2013-10-532341","volume":"123","author":"NP Shah","year":"2014","unstructured":"Shah NP, Guilhot F, Cortes JE, Schiffer CA, le Coutre P, Br\u00fcmmendorf TH, et al. Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study. Blood. 2014;123:2317\u201324. Long term follow up of patients on dasatinib demonstrating no increase in rate of AEs with longer follow up.","journal-title":"Blood"},{"key":"306_CR9","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/bjh.13108","volume":"168","author":"TH Br\u00fcmmendorf","year":"2015","unstructured":"Br\u00fcmmendorf TH, Cortes JE, de Souza CA, Guilhot F, Duvilli\u00e9 L, Pavlov D, et al. Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukaemia: results from the 24-month follow-up of the BELA trial. Br J Haematol. 2015;168:69\u201381.","journal-title":"Br J Haematol"},{"key":"306_CR10","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","volume":"362","author":"G Saglio","year":"2010","unstructured":"Saglio G, Kim D-W, Issaragrisil S, le Coutre P, Etienne G, Lobo C, et al. Nilotinib versus Imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med. 2010;362:2251\u20139.","journal-title":"N Engl J Med"},{"key":"306_CR11","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/S1470-2045(11)70201-7","volume":"12","author":"HM Kantarjian","year":"2011","unstructured":"Kantarjian HM, Hochhaus A, Saglio G, De Souza C, Flinn IW, Stenke L, et al. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. Lancet Oncol. 2011;12:841\u201351.","journal-title":"Lancet Oncol"},{"key":"306_CR12","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1038\/leu.2012.134","volume":"26","author":"RA Larson","year":"2012","unstructured":"Larson RA, Hochhaus A, Hughes TP, Clark RE, Etienne G, Kim DW, et al. Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up. Leukemia. 2012;26:2197\u2013203.","journal-title":"Leukemia"},{"key":"306_CR13","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1182\/blood.V122.21.92.92","volume":"122","author":"G Saglio","year":"2013","unstructured":"Saglio G, Hochhaus A, Hughes TP, Clark RE, Nakamae H, Kim D-W, et al. ENESTnd update: nilotinib (NIL) vs imatinib (IM) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) and the impact of early molecular response (EMR) and Sokal risk at diagnosis on long-term outcomes. Blood. 2013;122:92.","journal-title":"Blood"},{"key":"306_CR14","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1038\/bmt.2013.232","volume":"49","author":"XD Mo","year":"2014","unstructured":"Mo XD, Jiang Q, Xu LP, Liu DH, Liu KY, Jiang B, et al. Health-related quality of life of patients with newly diagnosed chronic myeloid leukemia treated with allogeneic hematopoietic SCT versus imatinib. Bone Marrow Transplant. 2014;49:576\u201380. Unexpected results of similar QOL between patients on TKIs and those receiving HCT.","journal-title":"Bone Marrow Transplant"},{"key":"306_CR15","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1007\/s11096-013-9876-7","volume":"36","author":"TC Chen","year":"2014","unstructured":"Chen TC, Chen LC, Huang YB, Chang CS. Imatinib adherence associated clinical outcomes of chronic myeloid leukaemia treatment in Taiwan. Int J Clin Pharmacol. 2014;36:172\u201381.","journal-title":"Int J Clin Pharmacol"},{"key":"306_CR16","doi-asserted-by":"crossref","first-page":"5401","DOI":"10.1182\/blood-2008-12-196543","volume":"113","author":"L Noens","year":"2009","unstructured":"Noens L, van Lierde MA, De Bock R, Verhoef G, Zachee P, Berneman Z, et al. Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. Blood. 2009;113:5401\u201311.","journal-title":"Blood"},{"key":"306_CR17","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1177\/1078155213520261","volume":"21","author":"KR Anderson","year":"2015","unstructured":"Anderson KR, Chambers CR, Lam N, Yau PS, Cusano F, Savoie ML, et al. Medication adherence among adults prescribed imatinib, dasatinib, or nilotinib for the treatment of chronic myeloid leukemia. J Oncol Pharm Pract. 2015;21:19\u201325.","journal-title":"J Oncol Pharm Pract"},{"key":"306_CR18","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/j.leukres.2015.07.004","volume":"39","author":"M Breccia","year":"2015","unstructured":"Breccia M, Efficace F, Sica S, Abruzzese E, Cedrone M, Turri D, et al. Adherence and future discontinuation of tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia. A patient-based survey on 1133 patients. Leuk Res. 2015;39:1055\u20139.","journal-title":"Leuk Res"},{"key":"306_CR19","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.leukres.2013.07.003","volume":"38","author":"F Efficace","year":"2014","unstructured":"Efficace F, Rosti G, Cottone F, Breccia M, Castagnetti F, Iurlo A, et al. Profiling chronic myeloid leukemia patients reporting intentional and unintentional non-adherence to lifelong therapy with tyrosine kinase inhibitors. Leuk Res. 2014;38:294\u20138.","journal-title":"Leuk Res"},{"key":"306_CR20","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1186\/1477-7525-11-167","volume":"11","author":"I Hirji","year":"2013","unstructured":"Hirji I, Gupta S, Goren A, Chirovsky DR, Moadel AB, Olavarria E, et al. Chronic myeloid leukemia (CML): association of treatment satisfaction, negative medication experience and treatment restrictions with health outcomes, from the patient\u2019s perspective. Health Qual Life Outcomes. 2013;11:167. Important data correlating QOL with medication experience.","journal-title":"Health Qual Life Outcomes"},{"key":"306_CR21","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1182\/blood-2013-04-495598","volume":"122","author":"M H\u00f6glund","year":"2013","unstructured":"H\u00f6glund M, Sandin F, Hellstr\u00f6m K, Bj\u00f6reman M, Bj\u00f6rkholm M, Brune M, et al. Tyrosine kinase inhibitor usage, treatment outcome, and prognostic scores in CML: report from the population-based Swedish CML registry. Blood. 2013;122:1284\u201392.","journal-title":"Blood"},{"key":"306_CR22","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.leukres.2007.07.022","volume":"32","author":"M Breccia","year":"2008","unstructured":"Breccia M, Cannella L, Montefusco E, Frustaci A, Pacilli M, Alimena G. Male patients with chronic myeloid leukemia treated with imatinib involved in healthy pregnancies: report of five cases. Leuk Res. 2008;32:519\u201320.","journal-title":"Leuk Res"},{"key":"306_CR23","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1111\/j.1365-2141.2007.06542.x","volume":"137","author":"K Ramasamy","year":"2007","unstructured":"Ramasamy K, Hayden J, Lim Z, Mufti GJ, Ho AY. Successful pregnancies involving men with chronic myeloid leukaemia on imatinib therapy. Br J Haematol. 2007;137:374\u20135.","journal-title":"Br J Haematol"},{"key":"306_CR24","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1200\/JCO.2005.04.6557","volume":"24","author":"P Ault","year":"2006","unstructured":"Ault P, Kantarjian H, O\u2019Brien S, Faderl S, Beran M, Rios MB, et al. Pregnancy among patients with chronic myeloid leukemia treated with imatinib. J Clin Oncol. 2006;24:1204\u20138.","journal-title":"J Clin Oncol"},{"key":"306_CR25","doi-asserted-by":"crossref","first-page":"5505","DOI":"10.1182\/blood-2007-10-114900","volume":"111","author":"SM Pye","year":"2008","unstructured":"Pye SM, Cortes J, Ault P, Hatfield A, Kantarjian H, Pilot R, et al. The effects of imatinib on pregnancy outcome. Blood. 2008;111:5505\u20138.","journal-title":"Blood"},{"key":"306_CR26","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s00277-015-2317-z","volume":"94","author":"R Palani","year":"2015","unstructured":"Palani R, Milojkovic D, Apperley JF. Managing pregnancy in chronic myeloid leukaemia. Ann Hematol. 2015;94:167\u201376. Excellent review on pregnancy and outcome.","journal-title":"Ann Hematol"},{"key":"306_CR27","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1176\/appi.neuropsych.12070177","volume":"26","author":"G Chang","year":"2014","unstructured":"Chang G, Meadows ME, Smallwood JA, Antin JH, Orav EJ. Cognitive and other predictors of change in quality of life one year after treatment for chronic myelogenous leukemia or myelodysplastic syndrome. J Neuropsychiatry Clin Neurosci. 2014;26:249\u201357.","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"306_CR28","first-page":"2113","volume":"22","author":"N Hamerschlak","year":"2014","unstructured":"Hamerschlak N, de Souza C, Cornacchioni AL, Pasquini R, Tabak D, Spector N, et al. Quality of life of chronic myeloid leukemia patients in Brazil: ability to work as a key factor. Support Care Cancer Off J Multinatl Assoc Support Care Cancer. 2014;22:2113\u20138.","journal-title":"Support Care Cancer Off J Multinatl Assoc Support Care Cancer"},{"key":"306_CR29","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s11899-015-0266-1","volume":"10","author":"J McNulty","year":"2015","unstructured":"McNulty J, Khera N. Financial hardship\u2014an unwanted consequence of cancer treatment. Curr Hematol Malig Rep. 2015;10:205\u201312.","journal-title":"Curr Hematol Malig Rep"},{"key":"306_CR30","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1200\/JCO.2013.52.9123","volume":"32","author":"SB Dusetzina","year":"2014","unstructured":"Dusetzina SB, Winn AN, Abel GA, Huskamp HA, Keating NL. Cost sharing and adherence to tyrosine kinase inhibitors for patients with chronic myeloid leukemia. J Clin Oncol. 2014;32:306\u201311.","journal-title":"J Clin Oncol"},{"key":"306_CR31","doi-asserted-by":"crossref","first-page":"4439","DOI":"10.1182\/blood-2013-03-490003","volume":"121","author":"Experts in Chronic Myeloid Leukemia","year":"2013","unstructured":"Experts in Chronic Myeloid Leukemia. The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. Blood. 2013;121:4439\u201342.","journal-title":"Blood"},{"key":"306_CR32","doi-asserted-by":"crossref","first-page":"3206","DOI":"10.1016\/j.ejca.2014.10.007","volume":"50","author":"F Millot","year":"2014","unstructured":"Millot F, Guilhot J, Baruchel A, Petit A, Leblanc T, Bertrand Y, et al. Growth deceleration in children treated with imatinib for chronic myeloid leukaemia. Eur J Cancer. 2014;50:3206\u201311.","journal-title":"Eur J Cancer"},{"key":"306_CR33","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.jpeds.2011.03.046","volume":"159","author":"H Shima","year":"2011","unstructured":"Shima H, Tokuyama M, Tanizawa A, Tono C, Hamamoto K, Muramatsu H, et al. Distinct impact of imatinib on growth at prepubertal and pubertal ages of children with chronic myeloid leukemia. J Pediatr. 2011;159:676\u201381.","journal-title":"J Pediatr"},{"key":"306_CR34","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1002\/pbc.24397","volume":"60","author":"KR Narayanan","year":"2013","unstructured":"Narayanan KR, Bansal D, Walia R, Sachdeva N, Bhansali A, Varma N, et al. Growth failure in children with chronic myeloid leukemia receiving imatinib is due to disruption of GH\/IGF-1 axis. Pediatr Blood Cancer. 2013;60:1148\u201353.","journal-title":"Pediatr Blood Cancer"},{"key":"306_CR35","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1056\/NEJM200411113512024","volume":"351","author":"T Seshadri","year":"2004","unstructured":"Seshadri T, Seymour JF, McArthur GA. Oligospermia in a patient receiving imatinib therapy for the hypereosinophilic syndrome. N Engl J Med. 2004;351:2134\u20135.","journal-title":"N Engl J Med"},{"key":"306_CR36","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/j.1365-2605.2007.00755.x","volume":"30","author":"M Nurmio","year":"2007","unstructured":"Nurmio M, Toppari J, Zaman F, Andersson AM, Paranko J, Soder O, et al. Inhibition of tyrosine kinases PDGFR and C-Kit by imatinib mesylate interferes with postnatal testicular development in the rat. Int J Androl. 2007;30:366\u201376. discussion 376.","journal-title":"Int J Androl"},{"key":"306_CR37","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1182\/blood-2015-06-648667","volume":"127","author":"N Hijiya","year":"2016","unstructured":"Hijiya N, Schultz KR, Metzler M, Millot F, Suttorp M. Pediatric chronic myeloid leukemia is a unique disease that requires a different approach. Blood. 2016;127:392\u20139.","journal-title":"Blood"},{"issue":"Suppl 2","key":"306_CR38","doi-asserted-by":"crossref","first-page":"S187","DOI":"10.1007\/s00277-015-2320-4","volume":"94","author":"FX Mahon","year":"2015","unstructured":"Mahon FX. Discontinuation of tyrosine kinase therapy in CML. Ann Hematol. 2015;94 Suppl 2:S187\u201393. Excellent review on the unique challenges in patients\u2019 children and adolescents with CML.","journal-title":"Ann Hematol"},{"key":"306_CR39","doi-asserted-by":"crossref","first-page":"2821","DOI":"10.1200\/JCO.2014.55.6910","volume":"32","author":"J Richter","year":"2014","unstructured":"Richter J, S\u00f6derlund S, L\u00fcbking A, Dreimane A, Lotfi K, Markev\u00e4rn B, et al. Musculoskeletal pain in patients with chronic myeloid leukemia after discontinuation of imatinib: a tyrosine kinase inhibitor withdrawal syndrome? J Clin Oncol. 2014;32:2821\u20133.","journal-title":"J Clin Oncol"}],"container-title":["Current Hematologic Malignancy Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-016-0306-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11899-016-0306-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-016-0306-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,15]],"date-time":"2020-09-15T12:22:23Z","timestamp":1600172543000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11899-016-0306-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2,15]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["306"],"URL":"https:\/\/doi.org\/10.1007\/s11899-016-0306-5","relation":{},"ISSN":["1558-8211","1558-822X"],"issn-type":[{"value":"1558-8211","type":"print"},{"value":"1558-822X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,2,15]]}}}